Envista Holdings Co. (NYSE:NVST) Stock Position Lifted by Xponance Inc.

Xponance Inc. grew its position in Envista Holdings Co. (NYSE:NVST) by 5.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 19,726 shares of the company’s stock after buying an additional 1,077 shares during the period. Xponance Inc.’s holdings in Envista were worth $381,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in NVST. Venturi Wealth Management LLC increased its stake in Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after purchasing an additional 1,638 shares during the last quarter. GAMMA Investing LLC raised its stake in Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after acquiring an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new position in Envista in the fourth quarter worth about $53,000. KBC Group NV boosted its stake in Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock valued at $152,000 after acquiring an additional 3,082 shares during the period. Finally, Glenmede Trust Co. NA bought a new position in shares of Envista during the third quarter valued at approximately $217,000.

Wall Street Analysts Forecast Growth

NVST has been the subject of a number of analyst reports. Wells Fargo & Company set a $19.00 price objective on Envista in a research report on Saturday, March 8th. Jefferies Financial Group boosted their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Mizuho started coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on shares of Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Finally, Piper Sandler upped their target price on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $20.18.

Envista Stock Performance

NVST opened at $17.55 on Thursday. The business has a 50 day moving average price of $19.67 and a two-hundred day moving average price of $19.59. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -2.70, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $23.00.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Research analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.